ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CDH17 Antibody-drug Conjugate HS-20110

Also written as “Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin”, “Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin” and “Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine”.

In hoffmann la roche’s pipeline, CDH17 ADC. Its studies are led by Hansoh Pharmaceutical Group.

Furthest: phase 2, since Dec 3, 20252 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group22 open or runningphase 2since Dec 3, 2025Feb 24, 2025Dec 31, 2026phase 1 · NCT06892379
  • Named in hoffmann la roche’s own pipeline as RG6975 CDH17 ADC (Hansoh), phase 1, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Hoffmann-La Roche.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2025First study: phase 1 study in Solid TumorsFirst studyNCT06892379 · 475 planned · United States, China
  2. Dec 3, 2025Phase 2 study in CRCPhase 2 reachedNCT07283367 · 502 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Solid TumorsNCT06892379
  2. Dec 31, 2029Primary completion: phase 2 study in CRCNCT07283367

TargetBeta

“CDH17 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-17 (CDH17) ”NCIt, by rule

Other programs on CDH17

ProgramCompanyFurthest phaseStudies
Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911ruleMabwell (Shanghai) Biosciencephase 22
AMT-676rulemultitude-therapeutics-incphase 22
Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324ruledualitybio-incphase 21
LM-350Sino Biopharmaceuticalphase 21
Anti-CDH17 Antibody-drug Conjugate YL217ruleMediLink Therapeutics (Suzhou)phase 11
Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217rulearrivent-biopharma-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07283367CRC · China2RecruitingDec 31, 2029502
NCT06892379Solid Tumors · United States, China1RecruitingDec 31, 2026475

How it is read

Names in the registry

  • “Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin”, 1 entry
  • “Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin”, 1 entry
  • “Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine”, 1 entry
  • “HS-20110 (Phase Ia:Dose escalation )”, 1 entry
  • “HS-20110 (Phase Ib:Dose expansion )”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.